For personal use only

ASX: CVB

15 July 2024

Updated Investor Presentation

Melbourne, Australia & Hatfield, Pennsylvania: CurveBeam AI Limited (ASX: CVB) releases the attached presentation to be delivered to investors and analysts today.

Release approved by the Board of Directors.

About CurveBeam AI Limited

CurveBeam AI (ASX:CVB) develops, manufactures and sells specialised medical imaging (CT) scanners, coupled with AI SaaS-based clinical assessment solutions, to support medical practitioners in the management of musculoskeletal conditions. The Company's flagship CT scanner, HiRise™, performs weight bearing CT scans as well as traditional non weight bearing CT scans, providing a range of advantages over the use of traditional CT or MRI devices. CurveBeam AI has more than 70 employees with its corporate office, AI and IP functions located in Melbourne, VIC, Australia and global operations headquarters in Hatfield, Pennsylvania, USA.

For further information go to https://curvebeamai.com

Investor / media enquiries

Matthew Wright
NWR Communications
+61 (0) 451 896 420
matt@nwrcommunications.com.au

ersonal use only

CurveBeam AI

INVESTOR PRESENTATION

July 2024

DISCLAIMER

ersonal use only

Introduction
THIS DOCUMENT IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO OR FROM THE UNITED STATES OF AMERICA OR TO ANY RESIDENT THEREOF, OR ANY OTHER JURISDICTION WHERE SUCH RELEASE, PUBLICATION OR DISTRIBUTION IS UNLAWFUL. THIS DOCUMENT IS NOT AN OFFER OR INVITATION TO BUY OR SELL SECURITIES.

This presentation has been prepared by CurveBeam AI Limited (ACN 140 706 618) (ASX:CVB) (**CurveBeam** or the **Company**) and contains summary information about CurveBeam and the business conducted by it as at 15 July 2024. The information in this presentation is for informational purposes only, does not purport to be complete and is not a prospectus, product disclosure statement or other disclosure document for the purposes of Chapter 6D or Part 7.9 of the *Corporations Act 2001* (Cth) (**Act**) or other offer document under Australian law or the law of any other jurisdiction.

The distribution of this document outside of Australia may be restricted by law and any such restrictions should be observed. This document may not be distributed or released to any person in the United States.
As further detailed below, none of CurveBeam, nor its advisers (**Advisers**) nor their respective affiliates, related bodies corporate (as defined in the Act) or security holders and their respective directors, officers, employees, partners, representatives, consultants, agents or advisers (each a **Limited Party** and together, the **Limited Parties**) guarantees or make any representation or warranty to, or takes responsibility for, the accuracy, reliability or completeness of the information contained in this presentation, to the **Recipient** of this document (you or the Recipient), and nothing contained in this document is, or may be relied upon as, a promise or representation, whether as to the past or future. To the maximum extent permitted by law, each Limited Party disclaims any liability for any loss arising from the use of information including representations or warranties or in relation to the accuracy or completeness of the information, statements, opinions or matters, express or implied, contained in, arising out of or derived from, or for omissions from, this presentation.

Not an offer or financial product advice
The information contained in this presentation is for informational purposes only and should not be considered, and does not contain or purport to contain, an offer, invitation, solicitation or recommendation with respect the purchase or sale of any securities in CurveBeam nor does it constitute legal, taxation, financial product or investment advice. The general information in this presentation has been prepared without taking into account the investment objectives, financial situation or particular needs of any particular person. Recipients of the presentation must undertake their own independent investigations, consideration and evaluation. By accepting this presentation, a Recipient agrees that if it proceeds further with its investigations, consideration or evaluation of investing in CurveBeam it will not in any way rely upon this document. Neither this presentation nor any of its contents will form the basis of any contract or commitment and it is not intended to induce or solicit any person to engage in any transaction nor is it intended to be used as the basis for making an investment decision.
CurveBeam recommends that potential investors consult their professional advisors as an investment in CurveBeam is subject to investment and other known and unknown risks, some of which are beyond the control of CurveBeam or its directors and therefore any investment is considered to be speculative in nature.

Forward looking statements
The information given in this presentation is given for illustrative purposes only and should not be relied upon as (and is not) an indication of CurveBeam's views on future performance or condition. Past performance cannot be relied upon as an indicator of future performance. This presentation contains certain forward-looking statements. The words 'forecast', 'estimate', 'like, 'anticipate', 'opinion', 'should', 'could', 'may' and other similar expressions are intended to identify future earnings, financial position and performance of CurveBeam. You are cautioned not to place undue reliance on these statements. These forward-looking statements are based on estimates, projections and assumptions made by CurveBeam about circumstances and events that have not yet taken place. Although due care and attention has been used in the preparation of these statements, such forward-looking statements are based on numerous assumptions regarding CurveBeam's present and future business strategies and the political, regulatory and economic environment in which CurveBeam will operate in the future and are subject to change without notice. Statements about market and industry trends, which are based on interpretations of current market conditions, may not be reasonable, and are not guarantees or predictions of future performance.
The actual results or performance of CurveBeam may be materially different from the results or performance expressed or implied by such forward-looking statements. No representation, warranty or assurance (express or implied) is given or made in relation to any forward-looking statement by any person (including any of the Limited Parties). In particular, no representation, warranty or assurance (express or implied is given that the occurrence of the events expressed or implied in any forward-looking statement in this presentation will actually occur). Subject to any continuing obligations under applicable law, the Company expressly disclaims any obligation or undertaking to provide any updates or revisions to any forward-looking statements in this presentation to reflect any change in expectations in relation to any forward-looking statement or any change in events, conditions or circumstances on which any statement is based.

Financial information
All numbers in this presentation are stated in Australian dollars (**A$**) unless stated otherwise.

CurveBeam AI

INVESTMENT HIGHLIGHTS



Deep Learning AI for automated bone segmentation, separation and measurement

CURVEBEAM AI IS A MEDICAL DEVICE COMPANY FOCUSED ON COMMERCIALISING WEIGHT BEARING CT SCANNERS & AI SAAS SOLUTIONS

First to market	• First to market, bilateral weight bearing CT scans • Enhanced HiRise™ CT provides in-office high-resolution 3D scans & future AI aided clinical assessment (subject to regulatory clearance)
Large TAM	• Combined US TAM >A$10bn market for device sales alone [1] • A$2.7bn for SaaS market (e.g. BMD assessment) per annum market [2]
Regulatory clearance	• FDA cleared, TGA listed, CE marked for CT imaging equipment • Enhanced HiRise™ FDA cleared July 2024 • Targeting submissions for AI aided tools – BMD, Autometrics & Ossview
Business model/ reimbursement	• Upfront CT sale with targeted high margin annuity SaaS sales • Targeting existing reimbursement levels for CT scans in global markets • Targeting existing BMD coding, payment, coverage for US group practices
Global distribution	• Over 170 generation 1, 2 & 3 scanners placed globally (circa 50 HiRise) • Users include key hospitals such as MGB, Mayo, Penn, Duke & HSS • Top tier distributor for the US market – Stryker Foot & Ankle

1. U.S. indicative install price (direct to clinician and partner sales) of HiRise™ x ~17,352 potential installation sites in the US (5,892 orthopaedic practices, 6,000+ Standalone imaging centres, 5,460 non-psychiatric hospitals)
2. 30.6m women over 65 recommended for screening based on US Preventive Services Taskforce screening recommendations x A$90, screened every 2 years (Medicare provides BMD reimbursement every 2 years).

ersonal use only

ersonal use only

EXECUTIVE SUMMARY

CurveBeam AI is a medical device company focused on commercialising weight bearing CT scanners

Products & solutions	• Weight Bearing CT (WBCT) provides 3D scans of joints under weight, enabling visualisation and assessment of condition under weight • The high resolution and 3D visualisation capabilities of the Company's devices enable new AI based clinical assessment tools • Developing a range of cloud-based AI modules to assist doctors in clinical assessment and surgical planning (alignment/bone quality)
Significant addressable markets	• Global Multibillion dollar market opportunity • Point of Care CT Imaging equipment – circa A$10bn [1] • Bone Health – bone mineral density (BMD) testing – circa A$2.7bn p.a. [2]
Recognised academic centers & global footprint	• Commercial stage company with revenue for FY23 of A$11.5m (circa 50% growth yoy) • 170+ device placements worldwide including well recognised medical institutions – UCLA, Duke, Mayo, HSS, MGB, PENN • US co-marketing & distribution agreement with Foot & Ankle (F&A) division of Stryker Corporation (NYSE:SYK) (Market cap circa US$120B+) • 47 placements of leading HiRise device to orthopaedic practices in the US, EU, Australia and other jurisdictions
Commercialisation/ reimbursement strategy	• Partnership with Stryker targets to expand its installed base of HiRise™ systems across the US market • Enhanced HiRise™ to address major requirement needed in group surgeon practices - higher energy HiRise for robotic system guides
Regulatory clearances	• First to market, FDA cleared, TGA and CE (MDR) Marked; Point of Care Bilateral Weight Bearing, high-resolution Cone Beam CT imaging equipment • Enhanced HiRise™ for robotic systems surgical planning 510(k) cleared July 2024 • Targeting FDA clearance in mid-CY2025 for the bone mineral density software module, Autometrics FY26, OssView (on hold)
Clinical validation & strong IP portfolio	• 37 granted patents and 27 pending patents internationally • 10+ years of clinical validation in bone fragility diagnostics with extensive peer reviewed publications on Weight Bearing CT • March 2024 published study of 500 patients [3] - CurveBeam AI's CubeVue Autometrics platform for presurgical planning in foot and ankle surgeries 97% faster than manual methods while being as accurate

1. U.S. indicative install price (direct to clinician and partner sales) of HiRise™ x ~17,352 potential installation sites in the US (5,892 orthopaedic practices, 6,000+ Standalone imaging centres, 5,460 non-psychiatric hospitals)
2. 30.6m women over 65 recommended for screening based on US Preventive Services Taskforce screening recommendations x A$90, screened every 2 years (Medicare provides BMD reimbursement every 2 years).
3. Foot and ankle surgery – March 2024 - Automatic software-based 3D-angular measurement for weight-bearing CT (WBCT) is valid – Richter et al 2024

CurveBeam AI

For personal use only

01

COMPANY OVERVIEW

CurveBeam AI

CURVEBEAM AI CT DEVICES & AI OUTPUT

CurveBeam AI has a range of CT imaging devices with visualisation applications in orthopaedics and bone health

	ORTHOPAEDIC VISUALISATION & PLANNING	BONE HEALTH CLINICAL AIDS (targeting a longer-term commercialisation)
Devices	 HiRise™ Weight Bearing CT imaging	 + InReach™ HR-pQCT High resolution wrist (InReach) & ankle (HiRise) scans for bone microstructure
Highlights	**IMPROVED WORKFLOW** **LOWER RADIATION DOSE** **REVENUE GENERATING** **MULTI-EXTREMITY SOLUTION** **POINT OF CARE**	
Features	**Custom surgical cut guides require a CT scan, where most patients are referred out for CT.** HiRise delivers a scan in-office, leading to 1 patient visit **Less radiation exposure** than conventional CT scanners **Existing favourable reimbursement** creates an attractive financial model for WBCT users HiRise is the first product capable of **natural bilateral WBCT from hip to foot** **Smaller and lower cost hardware** which requires **limited radiation shielding** enables imaging systems to be placed at **Point of Care locations**	
AI Output	 CubeVue Autometrics  Bone Mineral Density  Healthy Bone / Patient's Bone OssView (SFS)	

* This slide does not include all CurveBeam AI products

ersonal use only

CURVEBEAM TECHNOLOGY PLATFORM OVERVIEW

CurveBeam AI has regulatory clearances for WBCT devices in-market, including the new Enhanced HiRise™ – CVB targeting first automated BMD report for surgical planning for mid 2025

	SOLUTION	PRODUCTS		REGULATORY/ COMMERCIAL STATUS	US MARKET OPPORTUNITY	GROSS MARGIN	REVENUE OPPORTUNITY
ORTHOPAEDICS	Weight Bearing CT for Orthopaedic visual diagnostic support and treatment planning	HiRise™		In market Enhanced HiRise™ FDA 510(k) cleared	**~A$10bn**[1] (capital sales)	**~50%**	**A$645,000** per HiRise unit
ORTHOPAEDICS	Next generation AI bone segmentation and 3D modelling	AutoMetrics		FDA filing targeted for FY25 User subscription-based SaaS			
BONE HEALTH	AI delivered CT Bone Mineral Density (BMD) assessment for surgical planning for hip & knee scans	AI Generated BMD Report on the pre-existing MDCT & HiRise scans – SaaS based product		Enhanced HiRise™ FDA 510(k) cleared	TAM **A$2.7B** per annum[2] (BMD scan market)	Targeting 90%+	**~A$350,000** future p.a SaaS target per HiRise[3] (for BMD scans only)
BONE HEALTH		AI Generated CT BMD Report on the Enhanced HiRise at the hip – opportunistic scan only		BMD FDA filing targeted for end CY24			
BONE HEALTH	AI processed Structural Fragility Score of the ankle (OssView)	AI Generated OssView Report on the HiRise ankle & wrist scan – triage product for BMD result		In Development – OssView of the ankle; OssView wrist (developed but on hold)			

1. U.S. indicative install price (direct to clinician and partner sales) of HiRise™ x ~17,352 potential installation sites in the US (5,892 orthopaedic practices, 6,000+ Standalone imaging centres, 5,460 non-psychiatric hospitals)
2. 30.6m women over 65 recommended for screening based on US Preventive Services Taskforce screening recommendations x A$90, screened every 2 years (Medicare provides BMD reimbursement every 2 years).
3. Assumes 10 BMD CT scans per day, 5 days a week, 50 weeks a year at a target scan price of US$90 per scan (A$140 x circa 210 scans per month)

ersonal use only

CurveBeam AI

ersonal use only

02

WEIGHT BEARING CT

CurveBeam AI

For personal use only

WEIGHT BEARING CT OVERVIEW

- ✓ **Quicker and easier** to scan than traditional CT and MRI, with faster image acquisition time
- ✓ **High resolution** and **3D visualisation enables development of new AI based assessment tools**
- ✓ **Radiation dose lower** than traditional CT – up to 66% less than traditional CT
- ✓ **Smaller and lower-cost hardware** requiring limited radiation shielding infrastructure
- ✓ **Improves patient workflow in a group practice setting while creating CT revenue**



Hip to Foot in standing 3D

HiRise is the first product capable of WBCT of hip to foot in standing 3D



Weight bearing imaging key to accurate diagnosis

WBCT provides unique alignment data required to accurately access bone positioning under standing load

Serves more applications

The HiRise™ serves various orthopaedic sub-specialties in total knee, hip and ankle replacement planning in addition to implant manufacturers and 3D printed solution providers

CurveBeam AI

HIRISE IN ACTION (VIDEO)

For personal use only

CurveBeam AI

AI MODULES WILL TARGET SUBSCRIPTION BASED SAAS

CubeVue AutoMetrics aims to reduce hours of surgeon time for pre-surgical planning to a scan available in 15 minutes



APPLICATIONS

- Suspected hip, knee and ankle fractures
- Suspected osteoarthritis
- Bunions/Bunion correction
- AAFD reconstructions
- Joint replacements
- Charcot foot reconstruction
- High ankle sprain
- Lisfranc Injuries

THE PROBLEM

- Orthopaedic pre-treatment planning involves understanding of the structure and alignment of the foot – 26 bones & 33 joints
- To segment the bones in the foot and accurately assess bone geometry & alignment requires ~6 hours of manual effort
- Typically, surgeons will make crude manual measurements on 2D radiographs
- No reimbursement in place at this point
- Need standardised and objective results

THE SOLUTION

CurveBeam AI DLAI model aids in bone segmentation for accurately identifying key anatomical points

- Working 3D model with measurements in minutes for surgeons
- WBCT images drive improvements in accuracy & consistency
- CBAI has several key patents awarded in DLAI & non-AI for bone segmentation
- Targeting this IP for a platform solution for other CT modalities, in addition to WBCT (B2B)
- FDA filing expected in FY2025

For personal use only

CurveBeam AI

STRONG INVESTMENT PROPOSITION FOR SURGEONS

Targeting existing reimbursement codes - creates an attractive financial model

- The average Medicare reimbursement rate for scans of the lower extremity CPT code relevant to the HiRise™, pedCAT™ and LineUP™ was US$138.77 per scan in 2022
- With an initial capital cost of US$410,000 and assuming 10 scans per day, the payback period for a HiRise™ (excluding costs) is 1 year and 5 months
- If financed under a lease with an interest rate of 9%, the breakeven number of scans required to pay the machine off over a 5-year term is 2.83 scans per day (excluding costs)

Atlantic Orthopaedic Specialists, Virginia Beach, VA

Actual CurveBeam Customer – PedCat

Device up front cost: $179,000

Volume: 35 scans per month

Breakeven: 17 scans/month

Reimbursement range: $99.74 to $294.3[1]

Average reimbursement: $242.11

Gross revenue / month: $7,014.08

Device payback period of 2.5 years

1. US Payment and coverage varies extensively city to city, state to state and this example represents a specific model for a specific region of the US market

ersonal use only

CurveBeam AI

REGULATORY & REIMBURSEMENT OVERVIEW

Over 10 years of regulatory and clinical development and clearances underpin CurveBeam AI's industry leading position

Regulatory clearances	• FDA cleared, CE Marked and ARTG listed for HiRise - allows sales of HiRise in key markets – e.g. US, Europe and Australia/NZ • 510(k) for Enhanced HiRise cleared by the FDA • FDA filing targeted for Bone Mineral Density (late CY24) – targeting FDA clearance in mid CY25 • Cubevue Autometrics – priority lifted due to short term access to sales - FDA filing targeted for FY25 – value-add tool for users as a SaaS • OssView (wrist) – priority reduced - file on hold to support BMD & Autometrics trials/filings – clearance target will be revised when funds permit
Favourable reimbursement in US & Germany (CT only)	• Targeting favourable reimbursement[1] for CT scans (US/Germany/Australia/NZ) through existing CT CPT Codes & Payer Coverage • Targeting favourable reimbursement for BMD CT off HiRise (hip & knee surgeries) for US only – once BMD CT SaaS product FDA cleared
Clinical development	• Extensive peer reviewed publications on Weight Bearing CT • Over 10 years of clinical validation in bone fragility diagnostics using bone microstructure analysis • 2,000-woman, 8-year prospective study, to clinical end point of fragility fracture

1. 'Favourable' reimbursement is defined as where reimbursement is targeting existing codes/coverage and achieving enough reimbursed scans to pay for the device placement through a typical 4-to-5-year lease

ersonal use only

CurveBeam AI

ersonal use only

03

STRYKER F&A PARTNERSHIP

CurveBeam AI

STRYKER FOOT & ANKLE CO-MARKETING & DISTRIBUTION US PARTNERSHIP

US F&A division has access to 500 reps and 40 regional Sales Managers



STRYKER CORPORATION (NYSE:SYK) BACKGROUND

- Leading Orthopaedics & Spine multinational (NYSE) (MC circa US$130B)
- CurveBeam AI agreement is with the Foot & Ankle (F&A) division (2022)
- May 2023, F&A officially launched its HiRise™ promotion, distribution & financing program - qualified CurveBeam as an approved supplier
- Included access to Stryker's various 'Financing' options for customers
- HiRise™ is pre-loaded with Stryker F&A Prophecy surgical CT planning
- FY24 orders impacted by group practices wanting the same solution for total hip & knee – want one CT scanner for all lower extremity guides
- Enhanced HiRise™, targeting robotic system patient-specific datasets for hip and knee surgeries – CT scanner FDA cleared in July 2024
- A step change is targeted in HiRise™ placements for Q2 FY25, when it is anticipated validation of knee & hip datasets is in place

ersonal use only

CurveBeam AI

ersonal use only

04

COMMERCIALISATION STRATEGY

CurveBeam AI

LARGE MARKET OPPORTUNITY & ADOPTION BY LEADING CUSTOMERS

Potential US Addressable Market ~17,000+ potential installations (WBCT scanners only)[1] (A$bn)[2]



Customers[3]

Hospital Based

- Medium to large hospitals – can incorporate surgical planning for implants, fractures

Orthopaedic Surgeon Group Practices

- Surgeon group practices of two or more surgeons

Imaging Chains

- Orthopaedic diagnosis, surgical planning, fragility fracture diagnosis & management

Examples

- Mayo Clinics (all 3 major locations)
- NYU Langone Health
- UCLA Orthopaedic Institute for Children
- Kent State University – College of Podiatric Medicine
- Duke Orthopaedics
- Midwest Orthopaedics at Rush, Chicago
- Penn Medicine – Pennsylvania Hospital
- Hospices Civils De Lyon, France
- Massachusetts General Hospital, Boston
- Schön Klinik, Munich, Germany
- Hospital for Special Surgery, New York
- Ghent University Hospital, Belgium

#1 globally recognised specialist orthopaedic hospital in the US

1. Source: Frost & Sullivan
2. US HiRise indicative price US$410,000 x $1.50 US$/A$ potential installation sites in the US
3. ~17,352 potential installation sites in the US (5,892 orthopaedic practices, 6,000+ Standalone imaging centres, 5,460 non-psychiatric hospitals)

ersonal use only

CurveBeam AI

BMD AND OSSVIEW OVERVIEW

AI SaaS solutions for CT scans – an automated BMD result for surgical planning

HiRise a change agent



HiRise



BONE MINERAL DENSITY

- AI driven CT BMD report utilising existing MDCT scans and/or CurveBeam AI's high resolution CT scans for BMD testing in group surgical practice settings in the US market for hip and knee surgical plans
- Under development – target FDA 510(k) filing H2 CY24
- FDA clearance targeted in mid-2025
- Company expects to be able to provide BMD reports in conjunction with imaging for total joint, knee & hip replacements, for bone quality assessment
- **Targeting existing reimbursement in place in the US market for CT BMD testing**



OssView (SFS) – targeting HiRise scans of ankle

- AI generated report for aiding physicians in the assessment of bone quality in patients with non-osteoporotic BMD results
- Due to budget constraints – the integrated healthcare program is on hold and so too the FDA filing for OssView of the wrist (which was targeting Dec CY24 clearance)
- HiRise OssView at the ankle (feature under development) increasing priority over wrist to support trial
- Targeting a level one trial for establishing evidence based clinical & economic value of the combined tests in total joint surgical planning – with the goal of reducing aseptic loosening and periprosthetic fractures

ersonal use only

CurveBeam AI

TWO BUSINESS MODELS

Existing reimbursement codes/coverage targeted to drive both business models

1. Present HiRise CT Business Model

- Stryker sells HiRise for US$410,000 (circa A$645,000)
- CurveBeam AI transfers HiRise to Stryker
- Targeting US CPT code 73700 – CT scan lower extremity, under NCD 220.1
- Targeting circa 50% Gross Profit

2. Targeted Bone Mineral Density (BMD) SaaS Business Model

- HiRise – targeting 5 to 15 BMD reports per day (5-day wk, 50-wk year)
- Surgeon reimbursement ~US$140 per BMD report (circa ave. payment)
- CurveBeam AI targets a charge to surgeon of US$90 (~A$140) per report
- At 10 BMD's per day + **100 USA devices deployed – A$35m revenue**
- Targeting US CPT code 77078 – CT, BMD study, under NCD 150.3
- Targeting 90%+ Gross Profit



ersonal use only

CurveBeam AI

LAND & EXPAND COMMERCIALISATION STRATEGY

Over 170 first & second-generation installations worldwide, CurveBeam AI is well placed to upgrade its global install base

- ~17,000+ potential installations
- Utilises a combination of specialist distributors and direct salesforce to drive global sales
- US working with Stryker Corp (F&A)
- Significant sales pipeline to build on over 170 existing global installations
- Approx. 75% of placements in the US market



ersonal use only

FY24 QUARTERLY PURCHASE ORDERS

CurveBeam AI LineUp and PedCat WBCT devices are no longer available - stock is now sold



ersonal use only

ersonal use only

Next Generation WBCT Platform: SKYRISE ™

- SkyRise targets scans for dynamic structural detail about spinal alignment, joint orientation and supporting muscles. With future bone density & microstructure measures for better planning
- AI will target vertebrae with anatomical landmark recognition – to optimise right site & trajectory
- Longer term SkyRise will introduce a patented dual imaging capability to optimise assessment of soft & hard tissue – detail for paraspinal muscles (PSM) and thoracolumbar spine muscles
- SkyRise targets lumbar and cervical spine through a weight bearing (WB) and non-WB position. Both scans used to aid surgical decisions by assessing spinal stability and improved detail around occult back and leg pain
- Likewise for the shoulder, soft and hard tissue are considered important for planning total joint replacement – both tissues are important in assessing how the shoulder hangs for planning
- SkyRise Shoulder – targeting bone quality detail before first surgical cut is made into the shoulder

ersonal use only

05

EXPERIENCED BOARD AND MANAGEMENT

CurveBeam AI

EXPERIENCED BOARD

ROBERT LILLEY

Non-Executive Chairman, BA (Yale)

- 35 years' experience in medical device and diagnostics industry. Previously senior vice president of global sales and marketing, Digene Corporation (Nasdaq:DIGE), a molecular diagnostics company, which was subsequently acquired by Qiagen N.V. (NYSE:QGEN)
- Currently Chair of Immunexpress Pty Ltd, an Australian molecular diagnostics company

GREGORY BROWN

Chief Executive Officer, B.app.Sc, MBA

- 35 years healthcare experience
- Previously Baxter Diagnostics (Australia & UK), Roche Molecular (Switzerland/New York), Digene Corp (Washington DC/Germany)
- 2006-2012 ImpediMed CEO (IPD:ASX)
- 2014 – 2022 StraxCorp (Chairman & CEO)
- Board experience: Trinity Biotech (NASDAQ), Immunexpress (IXP), IPD(ASX), UniQuest (UQ)

ARUN SINGH

Executive Director, COO, CTO-CT, US president

BSc & Masters Degree in Electrical Engineering

- Founder, President and CEO of CurveBeam LLC
- Led the development of the first commercially viable Cone Beam CT imaging system for dental and maxillofacial imaging, with 9,000+ systems deployed today globally
- Awarded Lifetime Achievement Award by the AADMRT in 2016 for his visionary contributions to the advancement of cone beam CT

HASHAN DE SILVA

Non-Executive Director,

BSc (Medicine), MCom, CFA charterholder

- Founder and Managing Partner of KP Rx, a specialist healthcare fund manager
- Previously head of healthcare research at Karst Peak Capital, equity research analyst in healthcare at CLSA Limited and Senior Research Associate Analyst at Macquarie Group
- Director Pharmaxis Limited (ASX:PXS)

KATE ROBB

Non-Executive Director

BBus (Accounting), CA, GAICD

- 25 years' finance, governance, risk management and compliance experience
- Previous senior audit and risk roles at United Energy Limited (ASX:UEL), AGL Energy, ANZ
- Non-Executive Director Solvar Ltd (ASX:SVR), chair SVR audit and risk committee and a member of SVR nominations and remuneration committee

ersonal use only

CurveBeam AI

SENIOR MANAGEMENT

URA P AUCKLAND

CFO, Company Secretary

- B.Bus, G.Dip Company Secretarial Practice, Columbia University Snr Exec Program 2002. Graduate of CPA program
- Nearly 20 years' experience senior finance, operations and administrative roles in the technology and healthcare sectors
- Previously CFO and Company Secretary of ImpediMed Limited (ASX:IPD) and held various roles at PanBio Limited (ASX:PBO) including CFO, Company Secretary and Vice-President – Point of Care

YU PENG

CTO-AI, BSc & PhD

- Over 15 years' experience in computer vision and machine learning and oversees technical strategy and development at CurveBeam, including medical image analysis, machine learning and cloud computing
- PhD in Computer Vision and Machine Learning from the University of Newcastle, Australia. Visiting Professor position (honorary) in Artificial Intelligence (AI) at the University of Technology, Sydney, Australia from 2019 to 2022

S. TURNER DEAN

Chief Sales Officer

- 45 years of experience in healthcare and software
- VP Sales and Director of Business Development for CrossTec Corp., and Executive VP of AZZLY, Inc.
- Co-founded and sold CrossTec Security (aka Activeworx, Inc.) to Tripwire, Inc. during his tenure at CrossTec Corp
- BS in Economics from the University of Wisconsin-Whitewater

VINTI SINGH

Vice President of Marketing, BA (Journalism), MBA

- Over 14 years' communications and marketing experience
- Ms Singh joined CurveBeam LLC in 2012 and has served as Vice President of Marketing following the merger of CurveBeam AI and CurveBeam LLC in 2022
- Prior to this, Ms Singh was a reporter at the Hearst Connecticut Media Group
- Ms Singh has a Bachelor of Journalism and a Masters of Business Administration

ersonal use only

CurveBeam AI

For personal use only

06

NEAR TERM CATALYSTS

CurveBeam AI

MILESTONES OVER THE NEXT 24 MONTHS



Please note - due to budget constraints – the integrated healthcare program is on hold for OssView and so too the FDA filing for OssView of the wrist (was targeting December 2024). We will update the market when budget allows for funding the trial and filing has a timeline again.

ersonal use only

ersonal use only

CurveBeam AI

THANK YOU